AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04620551 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sub-clinical stimulation
Description: The third night of recording will involve sub-clinical thresholds of stimulation in all subjects.
Study NCT02604316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arabinoxylan
Description: 10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
Study NCT02604316 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beta- Glucan
Description: 10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
Study NCT02968069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NBI
Description: Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
Study NCT02603770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XueZhiKang
Study NCT02603770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovastatin
Study NCT04578860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy with Music Care app
Description: Listening to music with Music Care app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
Study NCT04578860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sound therapy with White Noise
Description: Listening to white noise with an app, every day, for 20 minutes, sitting up or lying down, at bedtime, with a headset or earbuds.
Study NCT04578860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual for sleep disorders
Description: No intervention
Study NCT00365456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parathyroid Hormone (PTH)
Description: Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
Study NCT00365456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: Orally once weekly as one 35 mg tablet.
Study NCT01846728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen suppression
Description: Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
Study NCT01925573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optune(NOVOTTF-100A)
Study NCT03834467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm 1 - Elevation Stimulus Video
Description: Subjects will watch a video that has been shown in previous studies to elicit an elevation response. This video shows a news story about a man saving the life of another man who falls onto the subway tracks.
Study NCT03834467 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Arm 2 - Control Stimulus Video
Description: Subjects will watch a nature video.
Study NCT01659242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate plus sulfasalazine
Description: ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose.
Study NCT01659242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: ARM 2:Leflunomide(LEF)~LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.~Methotrexate:Off
Study NCT01835015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLG561
Description: Administered by intravitreal injection, Day 1
Study NCT02520687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: 200mls daily for seven days
Study NCT02520687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-depleted beetroot juice
Description: 200mls daily for seven days
Study NCT03060044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler
Study NCT03060044 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone Easyhaler with charcoal
Study NCT03060044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus
Study NCT03060044 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seretide Diskus with charcoal
Study NCT01986920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 25%
Description: Low Dose Concentration of A-101 applied to one of 4 Target Lesions
Study NCT01986920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 32.5%
Description: Mid Dose Concentration of A-101 applied to one of 4 Target Lesions
Study NCT01986920 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A-101 40%
Description: High Dose Concentration A-101 applied to one of 4 Target Lesions
Study NCT01986920 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: A-101 Vehicle
Description: Placebo applied to one of 4 Target Lesions
Study NCT02238704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Regimen A calcium and iron/folic acid
Description: Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
Study NCT02238704 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Regimen B calcium and iron/folic acid
Description: Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
Study NCT01540253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PI3K inhibitor BKM120
Description: Given PO
Study NCT01540253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT01540253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01540253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01540253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00441974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adefovir dipivoxil
Description: adefovir dipivoxil once daily one tablet 10mg orally
Study NCT02263521 — intervention group
Intervention type: OTHER
Intervention: No intervention employed. Study is based on a cross-sectional observational design.
Study NCT01966328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 36% Resolvine Intravitreal Injection
Description: 36% Resolvine Intravitreal Injection
Study NCT01966328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 9% Resolvine Intravitreal Injection
Description: 9% Resolvine Intravitreal Injection
Study NCT03172832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PTBD
Description: Percutaneous access and tube placement into the bile duct
Study NCT03172832 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERC
Description: Endoscopic access and stent placement in the bile duct
Study NCT04165226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low level light therapy
Description: Patients will be offered 8 sessions of photobiomodulation using HPL Pagani Diode 808/915nm LLLT 3.2W (Fimad Elettromedicali SRL®, Catanzaro, Italy) with the parameters adjusted individually according to the surface area to be treated. Optimum dose is 10 joules/cubic centimeters. The patients will take 2 to3 sessions / week.
Study NCT04165226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2
Description: Patients will be offered 2 sessions of fractional carbon dioxide laser on a 4 weeks interval. Topical anesthesia with pridocaine cream will be applied under occlusion for 30 - 60 minutes before the session.~* Please update to the proper apparatus and parameters DEXA SmartXide DOT Fractional CO2 laser system 10600 nm (DEKA®, Florence, Italy) will be used with the following parameters adjusted individually to patients': power of 15-20 W, dwell time of 500-800 μs, spacing of 200-500 μm, and stack 2.
Study NCT04165226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Combined fractional CO2 laser and low level light therapy
Description: Combined treatment of both modalities (fractionational CO2 laser and low level light therapy). Please describe more....
Study NCT00988143 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2009-2010 Trivalent Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
Study NCT00988143 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 2008-2009 Trivalent Influenza Virus Vaccine
Description: 0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
Study NCT00988143 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Influenza Virus Vaccine
Description: 0.5 mL, Intramuscular
Study NCT01661855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riluzole
Description: 50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
Study NCT01661855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
Study NCT03889275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI5395
Description: Participants will receive multiple dose levels of MEDI5395 over several days as stated in arm description.
Study NCT03889275 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive IV infusion of durvalumab as stated in arm description.
Study NCT00304200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide and SU11248
Description: First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
Study NCT02486978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (109 g white bread)
Description: Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
Study NCT02486978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (109 g white bread)
Description: Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
Study NCT02486978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dose 1
Description: The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
Study NCT02486978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 1
Description: The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
Study NCT02486978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dose 2
Description: The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
Study NCT02486978 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dose 2
Description: The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
Study NCT03856853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: pirfenidone for SSc-ILD treatment
Study NCT03856853 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: as control
Study NCT03370120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: * Pharmaceutical Form: film-coated tablet~* Route of Administration: Oral use
Study NCT00507299 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced pediatric primary care
Description: Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
Study NCT00507299 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pediatric primary care
Description: Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
Study NCT04269148 — intervention group
Intervention type: OTHER
Intervention: Measurement of Quality of Life
Description: Quality of life will be measured using McMaster University Head and Neck Radiotherapy Questionnaire and The Functional Assessment of Cancer Therapy - Head and Neck Cancer Version 4
Study NCT02522676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Conventional PCNL will be performed.
Study NCT02522676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Mini PCNL will be performed.
Study NCT02522676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Ultra-mini PCNL will be performed.
Study NCT02522676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Micro PCNL will be performed.
Study NCT02522676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic kidney stone surgery
Description: Retrograde intrarenal surgery will be performed.
Study NCT02522676 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive kidney stone treatment
Description: Extracorporeal shock wave will be performed.
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, 500 mg calcium
Description: Berry flavoured sachet powder (500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, 500 mg calcium
Description: Berry flavoured sachet powder (500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 600 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 600 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (600 IU vitamin D + 500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 1200 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 1200 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (1200 IU vitamin D + 500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 4000 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
Study NCT05281107 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 4000 IU vitamin D + 500 mg calcium
Description: Berry flavoured sachet powder (4000 IU vitamin D + 500 mg calcium)
Study NCT01541189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
Study NCT01805167 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electrophysiological study of the interindividual variability of vocal performance
Study NCT00464321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Study NCT00464321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Study NCT00464321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Study NCT00464321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008
Description: 0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
Study NCT03526770 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: no intervention
Description: Unstimulated saliva samples are collected from the subject to measure the pH of saliva after 5, 15, 30, 45 and 60 minutes of consumption of the test carbonated drink without any intervention
Study NCT03526770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: tap water gargle
Description: The subject will use 10 ml of tap water as mouth rinse to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT03526770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 3: 0.2% Chlorhexidine
Description: The subject will use 10 ml of 0.2% Chlorhexidine mouth rinse (Rexidine®, Indoco Remidies Ltd, Mumbai, India) to swish for 60 seconds and spit. Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention
Study NCT03526770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 4: Fluoridated tooth paste
Description: The subject will Brush with fluoridated toothpaste-(Colgate Total®, Colgate-Palmolive Company, Mumbai, India) for 2 minutes using soft brush.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes using tooth paste as an intervention.
Study NCT03526770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 5: Polyol containing gum
Description: The subject will chew polyol containing gum (Orbit®, WrigleyCompany) for 5 minutes and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes chewing gum as an intervention.
Study NCT03526770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 6: 1% sodium bicarbonate solution
Description: The subject will use 10 ml freshly prepared 1% sodium bicarbonate w/v solution to swish for 60 seconds and spit.~Unstimulated saliva samples are collected from the subject to measure and record the pH of saliva at 15, 30 and 45 minutes after the subject completes the gargle as an intervention.
Study NCT02443896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pit and Fissure Sealant of permanent molars
Description: The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
Study NCT02443896 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No sealant of permanent molars
Description: No sealant applied to permanent molars.
Study NCT02884063 — intervention group
Intervention type: PROCEDURE
Intervention: NGS reading for Media Free DNA
Description: NGS reading for Media Free DNA instead of blstomer biopsy
Study NCT05837442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic Manual Therapy
Description: Occipital release, supraclavicular release, sternum mobilization, omentum minus release, liver pumping, diaphragm mobilization, grand maneuver for 3 minutes, general osteopathic manual therapy of the hip, knee and ankle was applied to each extremity for 90 seconds for a total of 3 minutes
Study NCT02888015 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: upper extremity exercise program
Description: five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
Study NCT03880487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KP-1199
Description: Single dose and Multiple ascending doses of KP-1199 oral capsules
Study NCT03880487 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Single dose and Multiple dose identical to active treatment but without KP-1199.
Study NCT03880487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone oral capsule
Description: 10 mg Oxycodone Capsules
Study NCT02730585 — intervention group
Intervention type: BIOLOGICAL
Intervention: C-reactive protein measurement
Description: All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.